Vor Biopharma Inc. Earnings Per Share (Basic)
Vor Biopharma Inc. (VOR) reported Earnings Per Share (Basic) of -$1.16 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Vor Biopharma Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.16.
- Vor Biopharma Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$5.11.
- Vor Biopharma Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$121.63.
- Vor Biopharma Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$251.24.
- Vor Biopharma Inc. earnings per share, basic for fiscal 2025 was -$70.50.
- Vor Biopharma Inc. earnings per share, basic for fiscal 2024 was -$34.03.
- Vor Biopharma Inc. earnings per share, basic for fiscal 2023 was -$1.75.
- Vor Biopharma Inc. earnings per share, basic for fiscal 2022 was -$2.33.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.16 10-Q · filed 2026-08-11 | -$5.80 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | -$5.11 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | -$70.50 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | -$121.63 10-Q · filed 2025-11-13 | -$368.68 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$378.11 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | -$251.24 10-Q · filed 2026-08-11 | -$12.56 10-Q · filed 2025-08-12 | -$256.88 10-Q · filed 2026-08-11 | -$12.84 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | -$5.21 10-Q · filed 2026-05-13 | -$0.26 10-Q · filed 2025-05-14 | ||||||
| 2024-12-31 | -$34.03 10-K · filed 2026-03-30 | -$1.70 10-K · filed 2025-03-20 | ||||||
| 2024-09-30 | -$8.05 10-Q · filed 2025-11-13 | -$0.40 10-Q · filed 2024-11-07 | -$1.54 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$25.25 10-Q · filed 2025-11-13 | -$1.26 10-Q · filed 2024-11-07 | -$2.17 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||
| 2024-06-30 | -$0.41 10-Q · filed 2025-08-12 | -$0.86 10-Q · filed 2025-08-12 | -$1.25 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$1.74 derived: net income ÷ weighted average shares · filed 2025-08-12 | ||||
| 2024-03-31 | -$0.45 10-Q · filed 2025-05-14 | -$0.84 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$1.33 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$1.78 derived: net income ÷ weighted average shares · filed 2025-05-14 | ||||
| 2023-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.88 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$1.32 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$1.75 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$0.49 10-Q · filed 2024-11-07 | -$0.94 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.37 10-Q · filed 2024-11-07 | -$1.88 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||||
| 2023-06-30 | -$0.45 10-Q · filed 2024-08-08 | -$0.88 10-Q · filed 2024-08-08 | -$1.38 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$1.96 derived: net income ÷ weighted average shares · filed 2024-08-08 | ||||
| 2023-03-31 | -$0.43 10-Q · filed 2024-05-09 | -$0.94 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$1.53 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$2.09 derived: net income ÷ weighted average shares · filed 2024-05-09 | ||||
| 2022-12-31 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-03-20 | -$1.14 derived: net income ÷ weighted average shares · filed 2024-03-20 | -$1.72 derived: net income ÷ weighted average shares · filed 2024-03-20 | -$2.33 10-K · filed 2024-03-20 | ||||
| 2022-09-30 | -$0.63 10-Q · filed 2023-11-07 | -$1.20 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.81 10-Q · filed 2023-11-07 | -$2.30 derived: net income ÷ weighted average shares · filed 2023-11-07 | ||||
| 2022-06-30 | -$0.58 10-Q · filed 2023-08-10 | -$1.19 10-Q · filed 2023-08-10 | -$1.67 derived: net income ÷ weighted average shares · filed 2023-08-10 | -$2.18 derived: net income ÷ weighted average shares · filed 2023-08-10 | ||||
| 2022-03-31 | -$0.61 10-Q · filed 2023-05-11 | -$1.10 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$1.60 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.10 derived: net income ÷ weighted average shares · filed 2023-05-11 | ||||
| 2021-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.99 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$1.49 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$2.10 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | -$0.50 10-Q · filed 2022-11-10 | -$1.00 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.62 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | -$0.50 10-Q · filed 2022-08-11 | -$1.13 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |